Key result
NT-proBNP levels ≥125 pg/ml were associated with higher odds of mild cognitive impairment compared to levels <125 pg/ml in adults without heart failure (OR 1.65; 95% CI 1.23-2.23).
Why the study?
Is subclinical elevation of NT-proBNP associated with mild cognitive impairment in a general population without heart failure?
Cross-Sectional (n=1,625)
Is subclinical elevation of NT-proBNP associated with mild cognitive impairment in a general population without heart failure?
Odds Ratio: 1.65 (95% CI 1.23–2.23)
Subclinical elevation of NT-proBNP is associated with mild cognitive impairment in individuals without manifest heart failure, independent of traditional cardiovascular risk factors.
May flag early cognitive risk in non-HF adults; leaves open whether NT-proBNP predicts dementia progression in prospective cohorts.
BACKGROUND: N-terminal pro-B type natriuretic peptide (NT-proBNP) is a marker of cardiac stress and is linked with silent cardiac diseases. While associations of cognitive impairment with manifest cardiovascular diseases are established, data on whether subclinical elevation of NT-proBNP levels below clinically established threshold of heart failure is related with cognitive functioning, especially mild cognitive impairment (MCI), is rare. OBJECTIVE: Aim of the present study was to investigate the cross-sectional association of NT-proBNP levels and MCI in a population-based study sample without heart failure. METHODS: We used data from the second examination of the population based Heinz-Nixdorf-Recall-Study. Subjects with overt coronary heart disease and subjects with NT-proBNP levels indicating potential heart failure (NT-proBNP≥300 pg/ml) were excluded from this analysis. Participants performed a validated brief cognitive assessment and were classified either as MCI [subtypes: amnestic-MCI (aMCI), non-amnestic-MCI (naMCI)], or cognitively-normal. RESULTS: We included 419 participants with MCI (63.1±7.4 y; 47% men; aMCI n = 209; naMCI n = 210) and 1,206 cognitively normal participants (62.42±7.1 y; 48% men). NT-proBNP-levels≥125 pg/ml compared to <125 pg/ml were associated with MCI in fully adjusted models (OR 1.65 (1.23;2.23) in the total sample, 1.73 (1.09;2.74) in men and 1.63(1.10;2.41) in women). For aMCI, the fully adjusted OR was 1.53 (1.04;2.25) and for naMCI, the fully adjusted OR was 1.34 (1.09; 166) in the total sample. CONCLUSION: Within normal ranges and without manifest heart failure, higher NT-proBNPlevels are associated with MCI and both MCI subtypes independent of traditional cardiovascular risk factors and sociodemographic parameters.
No takes yet. Share an insight, caveat, or question.
Kara et al. (2016) conducted a cross-sectional in Mild Cognitive Impairment (n=1,625). NT-proBNP levels ≥125 pg/ml vs. NT-proBNP levels <125 pg/ml was evaluated on Mild Cognitive Impairment (MCI) (OR 1.65, 95% CI 1.23-2.23). NT-proBNP levels ≥125 pg/ml were associated with higher odds of mild cognitive impairment compared to levels <125 pg/ml in adults without heart failure (OR 1.65; 95% CI 1.23-2.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: